je.st
news
Isis Pharmaceuticals Earns $2 Million from GSK for the Advancement of ISIS-TTR Rx
2013-12-03 00:36:37| Biotech - Topix.net
ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.
Tags: of
million
rx
pharmaceuticals
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||